Sunday 18 October 2026
Export FHTX’s income statement to Excel — free account
Foghorn Therapeutics Inc.
FHTX Healthcare Biotechnology
Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.
1.85
0.04
−2.12%
Follow FHTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 2 | 2 | 3 |
| 122.30% | 96.45% | 109.12% | 81.90% | ||
| (28.10%) | (30.82%) | (31.33%) | (30.06%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(66.97%) | (70.47%) | (60.08%) | (53.39%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.41) | (1.37) | (1.26) | (1.19) | |
Free Cash Flow |
(88.88) | (86.15) | (87.40) | (84.31) | |
Capital Expenditures |
(0.53) | (0.05) | — | (0.07) | |
| Other line items | |||||
Cash ROIC |
(96.74%) | (166.81%) | (80.57%) | (97.43%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
342.31% | 276.51% | 290.88% | 214.57% | |
Selling, General and Administrative Expense of Revenue |
110.56% | 89.13% | 95.28% | 71.81% | |
Share Based Compensation of Revenue |
43.40% | 33.64% | 35.75% | 26.97% | |
Operating CF/Net income |
1.23 | 1.16 | 1.16 | 1.30 | |
Depreciation/Fixed assets |
0.01 | 0.73 | 0.73 | 0.30 | |
Capex/Depreciation |
(5.19) | (0.04) | 0.00 | (0.16) | |
Revenue per Share |
0.39 | 0.49 | 0.41 | 0.52 | |
Operating CF per Share |
(1.40) | (1.37) | (1.26) | (1.19) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 |
Columns are period end dates